Thursday, 7 July 2022
  
Login

Australia's most trusted
source of pharma news

Thursday, 07 July 2022
Listen to this story 
News

Nice work: 200% growth Q1

Posted 19 May 2022 PM

Companies that market vaccines and therapies to combat Covid continued to lead revenue growth in the first quarter of 2022, however investor interest is declining.

Twelve of the industry's top 23 companies achieved double-digit growth, with the top five - all fuelled by sales of Covid products - each surpassing a 50 per cent revenue increase compared with the first quarter of last year.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (7)

Sales & Customer Relations (26)

Access & Reimbursement (2)

Clinical & Medical, R&D (14)

Regulatory, Pharmacovigilance & QA (8)

Devices (1)

Other (29)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.